Unleashing the Immune System: Treatment and Adverse Event Management for the Immuno-Oncology Patient

Recorded On: 08/22/2018

This presentation will discuss the clinical indications, administration, and adverse-event implications of novel immuno-oncology agents. As these therapies have emerged, it is evident that the side-effect profile and management of these agents are vastly different from traditional chemotherapy. Immuno-oncology-specific education for health care workers and patients is critical to the safe delivery and implementation of high-quality care. Throughout this presentation, the background of employing the immune system to fight cancer, and using real-patient scenarios to demonstrate best practices for infusion clinicians in the care, quality, and education of the immuno-oncology patient will be explored.

Learning Outcomes: At the conclusion of this presentation, participants will be able to:

  • Identify 3 signs and symptoms of an immune-mediated adverse event.
  • Discuss the importance of early identification and treatment of adverse events.
  • Verbalize 3 different methods of education for immuno-oncology patients.

​Megan Derr, MSN, RN, CMSRN, AONCS®

Megan Derr, MSN, RN, CMSRN, AONCS®, is an oncology quality and evidence-based practice specialist at the Lehigh Valley Cancer Institute in Allentown, Pennsylvania. She is certified by the Oncology Nursing Certification Corporation as an advanced oncology clinical nurse specialist. A highlight in her current role has been educating the cancer institute about immuno-oncology agents, their side effects, and adverse event management. 

CRNI® RUs: This session has been approved for 1 CRNI® recertification unit and meets the non INS Meeting criteria.

Contact Hours: This session has been approved for 1 contact hour

Expiration date for receipt of contact hours: August 22, 2021

Key:

Complete
Failed
Available
Locked
Webinar
Live event: 08/22/2018 at 1:00 PM (EDT) You must register to access.
Webinar Evaluation
Certificate
Printable Certificate You must register to access.